YHO-13351 Inhibitor

Name: YHO-13351 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754138
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754138

YHO-13351 (free base) is the water-soluble prodrug of YHO-13177, and is a potent and specific BCRP inhibitor. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

YHO-13351, Inhibitor

Full Product Name

YHO-13351 free base

Product Gene Name

YHO-13351, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

483.62

Solubility

DMSO: 100mg/mL (206.77mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C26H33N3O4S

SMILES

N#C/C(C1=CC=C(OC)C(OC)=C1)=C\C2=CC=C(N3CCC(OC(CN(CC)CC)=O)CC3)S2

CAS Number

912288-64-3

Target & IC50

Others

In Vitro

YHO-13351 is rapidly converted into YHO-13177 after its oral or intravenous administration in mice. In an HCT116/BCRP xenograft model, Coadministration of irinotecan with YHO-13351 significantly increases the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth, whereas irinotecan alone has little effect in these tumor models.

Product References and Citations for YHO-13351, inhibitor

Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63.
Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63.
Shishido Y, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013 Apr;33(4):1379-86.
Shishido Y, et al. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan. Anticancer Res. 2013 Apr;33(4):1379-86.

Other Notes

Small volumes of YHO-13351, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for YHO-13351 purchase

MBS5754138 is an inhibitor targeting YHO-13351. Also known as YHO-13351 free base.

YHO-13351 Inhibitor

Product Overview

Structure of YHO-13351, inhibitor

Related Product Information for YHO-13351, inhibitor

Product References and Citations for YHO-13351, inhibitor

Other Notes

Searchable Terms for YHO-13351 purchase